EN DE
Watch Fusen Pharmaceutical Company Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Fusen Pharmaceutical Company Ltd (1652) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Fusen Pharmaceutical Company Ltd stock HK$1.33, price HK$0.90, upside +47.8%, quality 49 out of 100. Rating: undervalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG370981030

FP Fusen Pharmaceutical Company Ltd logo Thin data Nov 15, 2026

Fusen Pharmaceutical Company Ltd

1652 · HK

Cheap (32% below fair value), company just good enough and rising price: meets all 3 rules.

Get notified free when this changes
Fair value HK$1.33 · Undervalued 
Rising price (uptrend) 
Low debt 
Generates free cash flow 
Even on cautious assumptions the value is 17% above the price (HK$1.05). 
Quality 49/100 
Mixed vs. peers (5/12) 
Weak Growth (revenue 5y −10.9 %/yr in CNY) 
Loss-making · -0.8% net margin (TTM) 
Narrow moat 18/100 · thin data
Thin data 
Watch Fusen Pharmaceutical Company Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$3.35 HK$0.2440 Fair Value HK$1.33 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range HK$0.2440 – HK$3.35 · fair‑value band HK$1.05 – HK$1.59 · the HK$0.9000 price screens below the HK$1.33 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Fusen Pharmaceutical Company in your weekly email

Every Wednesday you see whether Fusen Pharmaceutical Company is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Fusen Pharmaceutical Company Limited, an investment holding company, engages in the manufacturing and sale of pharmaceutical products in the People's Republic of China.

Show moreShow less

The company offers Shuanghuanglian oral solutions and injections; Sanhuang tablet; heat-clearing and detoxicating oral solutions; Flunarizine hydrochloride capsules; Sanhuang tablets; compound ferrous sulfate granules; and other pharmaceutical products.

It is also involved in manufacturing and sale of pharmaceutical package materials; research and development of pharmaceutical products; sale of construction materials and pharmaceutical products; and provision of business management and consulting services.

Its medicines are used for the treatment of heat-clearing and detoxification, cardiovascular and cerebrovascular, antihypertensive and hypoglycemic, tonifying, qi-regulating, anti-anemia, and antibacterial and anti-inflammatory.

Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.

Stock analysis

Fusen Pharmaceutical Company Ltd (1652) currently trades at HK$0.9000, while our model-based Fair Value estimate is HK$1.33, implying the stock looks roughly 32% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of HK$1.46 per share, and 8 of the 10 models we run sit above the HK$0.9000 price.

Bear case: the Asset-Based group reads lowest at HK$0.3500, and 2 of the 10 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$1.05 (bear) to HK$1.59 (bull), the price of HK$0.9000 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Fusen Pharmaceutical Company Ltd reported revenue of 273M CNY in FY2025 versus 386M CNY in FY2021, a compound −8.2%/yr. Reported net income was −11.8M CNY in FY2025.

Key figures

Market cap HK$665M (≈ $84.8M) Micro · P/S ratio 2.24 · Net margin −0.8% · Return on equity −0.7% · Return on assets (EBIT) 0.3% (5-year average) · Operating margin −5.0% · Revenue (TTM) 276M CNY · Revenue growth (YoY) +2.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).

What moves the price

The share trades about 35% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 48%, 1652 screens cheaper than that median.

Fair Value models

Bear HK$1.05 Fair Value HK$1.33 Bull HK$1.59
Price HK$0.9000 · Upside +47.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$1.16 HK$1.46 HK$1.93 82
Growth DCF HK$1.19 HK$1.47 HK$1.88 80
5Y EBITDA Exit HK$0.8800 HK$1.11 HK$1.42 77
All 10 models by family
DCF Models
FCF DCF HK$1.16 HK$1.46 HK$1.93 82
5Y Revenue Exit HK$1.05 HK$1.42 HK$1.94 73
5Y EBITDA Exit HK$0.8800 HK$1.11 HK$1.42 77
10Y Revenue Exit HK$1.08 HK$1.33 HK$1.59 68
10Y EBITDA Exit HK$1.00 HK$1.16 HK$1.32 70
Multiples
EV/EBITDA HK$0.2100 HK$0.4100 HK$0.6100 64
EV/Revenue HK$0.5300 HK$0.9200 HK$1.31 52
Asset-Based
NCAV (Graham) HK$0.2600 HK$0.3500 HK$0.5200 54
Growth DCF
Growth DCF HK$1.19 HK$1.47 HK$1.88 80
Rev-Margin DCF HK$1.05 HK$1.45 HK$1.93 73

Open the full fair value analysis →

Quality Score breakdown

Overall quality 49/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 45
Are margins and returns getting better?
Cashflow 79
Do the profits arrive as real cash?
Financial strength 29
Debt, balance sheet and risk of trouble
Investment 69
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 35
Distance to the 52-week high, does not count
New shares 85
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 17/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−16.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.9%
Start year 2020 (pandemic). Over 10 years: −2.9% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
21.2% (2020) → −0.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+3.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +1.6% a year for the price.

Watch 1652, get fair value alerts →

Compare Fusen Pharmaceutical Company Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks

Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 49 · Below median
Fair Value upside +47.8% · Top 25%
Profitability
Return on assets −0.9% · Below median
Net margin (12 months) −0.8% · Below median
Operating margin (12 months) −5.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 2.5% · Below median
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.57× · Cheaper than median
P/S (12 months) 2.05× · Cheaper than median
Price / free cash flow (fiscal year) 8.1× · Cheapest 25%
EV/EBITDA 14.5× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)97 · sector 18
FUTURE (revenue growth)13 · sector 26
PAST (return on equity)0 · sector 25
HEALTH (low debt)99 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.82 $113.53 +35% vs 1652
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.07 ¥53.04 +10% vs 1652
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,880 ₹1,983 +5% vs 1652
Haleon plc HLN $9.17 $8.47 −8% vs 1652
Merck KGaA MRK €149.60 €108.83 −27% vs 1652
Galderma Group GALD CHF 191.40 CHF 112.30 −41% vs 1652
Takeda Pharmaceutical Company TAK $21.43 $11.20 −48% vs 1652
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs 1652
Teva Pharmaceutical Industries Limited TEVA $44.50 $20.74 −53% vs 1652
Divi's Laboratories Limited DIVISLAB ₹11,442 ₹1,567 −86% vs 1652

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Fusen Pharmaceutical Company Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Fusen Pharmaceutical Company Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1652

Frequently asked questions

Is Fusen Pharmaceutical Company Ltd (1652) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of HK$1.33 versus a price of HK$0.9000, about +48% upside (undervalued).
What is the fair value of 1652?
Our model-based fair value for Fusen Pharmaceutical Company Ltd is HK$1.33 (as of Nov 15, 2026), built from audited fundamentals. The current price: HK$0.9000.
What is the quality score of 1652?
Fusen Pharmaceutical Company Ltd has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fusen Pharmaceutical Company Ltd (1652)?
Our model-based price target is the fair value of HK$1.33 (as of Nov 15, 2026) from 10 valuation models. Cautious scenario HK$1.05, optimistic scenario HK$1.59. It is a calculation from audited fundamentals, not an analyst target.
What is the Fusen Pharmaceutical Company Ltd stock forecast for 2026?
Our models put fair value at HK$1.33, about +48% upside versus a price of HK$0.9000 (undervalued). Cautious scenario HK$1.05, optimistic scenario HK$1.59. The calculation is refreshed regularly with new filings.
What is the revenue of Fusen Pharmaceutical Company Ltd (1652)?
Fusen Pharmaceutical Company Ltd reported trailing-twelve-month revenue of about 276M CNY (latest available figure, as of Nov 15, 2026).
What growth is priced into Fusen Pharmaceutical Company Ltd (1652)?
For today's price to be fair in a discounted-cash-flow model, Fusen Pharmaceutical Company Ltd would have to grow free cash flow by 3.3 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue fell 10.9 % per year. As of Nov 15, 2026.
What discount rate (WACC) does the fair value of 1652 use?
Our models discount Fusen Pharmaceutical Company Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.21, country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Fusen Pharmaceutical Company Ltd that is +3.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Fusen Pharmaceutical Company Ltd (1652) delivered so far?
Over the past 5 years revenue at Fusen Pharmaceutical Company Ltd shrank 10.9 % a year. The price currently implies free-cash-flow growth of +3.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Fusen Pharmaceutical Company Ltd (1652) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Fusen Pharmaceutical Company Ltd (+3.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Fusen Pharmaceutical Company Ltd (1652)?
The free-cash-flow yield on the price is 12.38 %: that much free cash flow Fusen Pharmaceutical Company Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Fusen Pharmaceutical Company Ltd (1652)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fusen Pharmaceutical Company Ltd it is HK$1.33 per share (as of Nov 15, 2026), against a price of HK$0.9000. It is the blended result of 10 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Fusen Pharmaceutical Company Ltd stock overvalued or undervalued in 2026?
As of Nov 15, 2026, 1652 trades below its calculated fair value: price HK$0.9000, fair value HK$1.33, a gap of about +48% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1652?
No. The price is what the market pays today (HK$0.9000); the fair value is what the company's own numbers justify (HK$1.33). For Fusen Pharmaceutical Company Ltd the two are HK$0.4300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Fusen Pharmaceutical Company Ltd worth?
The market values Fusen Pharmaceutical Company Ltd at about HK$665M (market capitalisation, as of Nov 15, 2026). Per share that is HK$0.9000; our models calculate a fair value of HK$1.33 per share.
What do the bullish and bearish scenarios say about 1652?
Our models span a range for Fusen Pharmaceutical Company Ltd: cautious scenario HK$1.05, base HK$1.33, optimistic HK$1.59 per share (as of Nov 15, 2026, price HK$0.9000). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Fusen Pharmaceutical Company Ltd (1652)?
Balance-sheet figures for Fusen Pharmaceutical Company Ltd (as of Nov 15, 2026): return on equity −0.7%, debt of 0.02 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 1652 from its 52-week high?
Fusen Pharmaceutical Company Ltd trades at HK$0.9000, about 35% below its 52-week high of HK$1.39 and 25% above the low of HK$0.7200 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$1.33 is for.
Which stocks are comparable to Fusen Pharmaceutical Company Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fusen Pharmaceutical Company Ltd stock attractive at the current price?
The data as of Nov 15, 2026: price HK$0.9000, calculated fair value HK$1.33 (+48%), Quality Score 49/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1652 calculated?
We run Fusen Pharmaceutical Company Ltd through 10 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of HK$1.33 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Fusen Pharmaceutical Company Ltd currently trades 32% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fusen Pharmaceutical Company Ltd (1652)?
The closing price on Nov 13, 2026 was HK$0.9000. Our model-based fair value is HK$1.33, about +48% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fusen Pharmaceutical Company Ltd right now?
The large discount to fair value meets weak quality (49/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (HK$1.05). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Fusen Pharmaceutical Company Ltd

How large is the market capitalisation of Fusen Pharmaceutical Company Ltd (1652)?
The market capitalisation of Fusen Pharmaceutical Company Ltd is HK$665M (≈ $84.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fusen Pharmaceutical Company Ltd (1652)?
The price-to-sales ratio of Fusen Pharmaceutical Company Ltd is 2.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Fusen Pharmaceutical Company Ltd (1652)?
The net margin of Fusen Pharmaceutical Company Ltd is −0.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Fusen Pharmaceutical Company Ltd (1652)?
The return on equity (ROE) of Fusen Pharmaceutical Company Ltd is −0.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fusen Pharmaceutical Company Ltd (1652)?
On an EBIT basis the return on assets of Fusen Pharmaceutical Company Ltd is 0.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fusen Pharmaceutical Company Ltd (1652)?
The operating margin of Fusen Pharmaceutical Company Ltd is −5.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fusen Pharmaceutical Company Ltd (1652)?
Revenue at Fusen Pharmaceutical Company Ltd is growing 2.5% versus a year earlier (3y avg −17.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Fusen Pharmaceutical Company Ltd (1652)?
Earnings per share at Fusen Pharmaceutical Company Ltd are growing 42.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Fusen Pharmaceutical Company Ltd (1652) carry?
The net debt of Fusen Pharmaceutical Company Ltd is 240M CNY (fiscal year 2025, ≈ 3.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Fusen Pharmaceutical Company Ltd in the live analysis

One click puts Fusen Pharmaceutical Company Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.